Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)
- 31 December 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (13-14) , 2409-2411
- https://doi.org/10.1016/0959-8049(95)00331-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.Journal of Clinical Oncology, 1994
- Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.Journal of Clinical Oncology, 1993
- Modeling Interpatient Pharmacodynamic Variability of EtoposideJNCI Journal of the National Cancer Institute, 1991
- Second generation analogs of etoposide and mitomycin CCancer Treatment Reviews, 1990
- Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30Investigational New Drugs, 1990
- Carboplatin and etoposide pharmacokinetics in patients with testicular teratomaCancer Chemotherapy and Pharmacology, 1989
- Hypersensitivity Reactions to Etoposide A Case Report and Review of the LiteratureAmerican Journal of Clinical Oncology, 1988
- Study of histamine release induced by acute administration of antitumor agents in dogsCancer Chemotherapy and Pharmacology, 1988